HBF-0259-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEHBF-0259Cat.No.:HY-126970CASNo.:957011-15-3分?式:C??H??Cl?FN?分?量:364.2作?靶點(diǎn):HBV作?通路:Anti-infection儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:100mg/mL(274.57mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM2.7457mL13.7287mL27.4574mL5mM0.5491mL2.7457mL5.4915mL10mM0.2746mL1.3729mL2.7457mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.08mg/mL(5.71mM);Clearsolution1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(5.71mM);Clearsolution3.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(5.71mM);Clearsolution4.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(5.71mM);Clearsolution5.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(5.71mM);ClearsolutionBIOLOGICALACTIVITY?物活性HBF-0259?種有效和選擇性的?型肝炎病毒(HBV)表抗原(HBsAg)分泌抑制劑，在HepG2.2.15細(xì)胞中的EC50值為1.5μM。HBF-0259對(duì)HBVDNA合成沒有響。體外研究HBF-0259(0.0158-50.0μM)inhibitstheHBsAgsecretion(EC50=1.5μM)inHepDE19cells,withanCC50of>50μM[1].HBF-0259(2-8μM)significantlyreducestheabundanceofbothLandMinthesupernatantsofHepG2.2.15cells[1].REFERENCES[1].DoughertyAM,et,al.Asubstitutedtetrahydro-tetrazolo-pyrimidineisaspecificandnovelinhibitorofhepatitisBvirussurfaceantigensecretion.AntimicrobAgentsChemother.2007Dec;51(12):4427-37.[2].YuW,et,al.Design,synthesis,andbiologicalevaluationoftriazolo-pyrimidinederivativesasnovelinhibitorsofhepatitisBvirussurfaceantigen(HBsAg)secretion.JMedChem.2011Aug25;54(16):5660-70.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.